Resources Archive - Page 34 of 46

Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1α

WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry describing the optimization of a...

Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step

WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of...

Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit...

Expansion of the E3 ligase toolbox has the potential to dramatically advance the field of targeted protein degradation. WuXi AppTec...

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic...

KRAS-related Genetically Engineered Cell Lines and In Vivo Models

KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to...

WuXi Biology Fact Sheet

Expertise in all major disease areas and all major target classes, enabling discovery for all therapeutic modalities World class antiviral...

Targeted Protein Degradation

WuXi AppTec utilizes state-of-the-art techniques to support drug discovery teams focused on targeted protein degradation. Our services include a broad...

In Vitro Imaging Services

Offering a comprehensive platform of in vitro imaging-based assays to screen compounds for cancer, inflammation, and autoimmune diseases. Our services...

CDK4/6 Inhibitor Resistant Breast Cancer Models

Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including: In vitro induced Palbociclib resistant MCF-7 cell line...

Knowledge Library